LEXICON PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
LXRX$1.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands)
| Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Additional · Other | |||||||
| Common Stock · Paid-In · Accumulated · Comprehensive · Treasury | |||||||
| Shares | Par Value | Capital | Deficit | Gain (Loss) | Stock | Total | |
| Balance at December 31, 2020 | 142,289 | $142 | $1,561,096 | $(1,400,018) | $(6) | $(4,843) | $156,371 |
| Stock-based compensation | — | — | 10,577 | — | — | — | 10,577 |
| Issuance of common stock under an Open Market Sale Agreement, net of issuance fees | 6,177 | 6 | 35,485 | — | — | — | 35,491 |
| Issuance of common stock under Equity Incentive Plans | 1,616 | 2 | 1,591 | — | — | — | 1,593 |
| Repurchase of common stock | — | — | — | — | — | (2,675) | (2,675) |
| Net loss | — | — | — | (87,758) | — | — | (87,758) |
| Unrealized loss on investments | — | — | — | — | (4) | — | (4) |
| Balance at December 31, 2021 | 150,082 | $150 | $1,608,749 | $(1,487,776) | $(10) | $(7,518) | $113,595 |
| Stock-based compensation | — | — | 11,520 | — | — | — | 11,520 |
| Issuance of common stock under Equity Incentive Plans | 32 | — | — | — | — | — | — |
| Issuance of common stock, net of issuance fees | 39,100 | 39 | 94,166 | — | — | — | 94,205 |
| Issuance of equity-classified warrants | — | — | 1,030 | — | — | — | 1,030 |
| Issuance of treasury stock | — | — | (6,321) | — | — | 6,321 | — |
| Repurchase of common stock | — | — | — | — | — | (864) | (864) |
| Net loss | — | — | — | (101,944) | — | — | (101,944) |
| Unrealized loss on investments | — | — | — | — | (418) | — | (418) |
| Balance at December 31, 2022 | 189,214 | $189 | $1,709,144 | $(1,589,720) | $(428) | $(2,061) | $117,124 |
| Issuance of equity-classified warrants | — | — | 307 | — | — | — | 307 |
| Stock-based compensation | — | — | 14,340 | — | — | — | 14,340 |
| Issuance of common stock, net of fees | 55,288 | 55 | 138,768 | — | — | — | 138,823 |
| Issuance of common stock under Equity Incentive Plans | 1,291 | 1 | (1) | — | — | — | — |
| Repurchase of common stock | — | — | — | — | — | (824) | (824) |
| Net loss | — | — | — | (177,119) | — | — | (177,119) |
| Unrealized gain on investments | — | — | — | — | 459 | — | 459 |
| Balance at December 31, 2023 | 245,793 | $245 | $1,862,558 | $(1,766,839) | $31 | $(2,885) | $93,110 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.